NeuroSense Therapeutics (NASDAQ:NRSN) Shares Down 6.6% – Here’s Why

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) traded down 6.6% during mid-day trading on Monday . The stock traded as low as $0.6701 and last traded at $0.6870. 297,758 shares traded hands during mid-day trading, an increase of 140% from the average session volume of 123,877 shares. The stock had previously closed at $0.7352.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research report on Friday, May 8th. Roth Mkm assumed coverage on shares of NeuroSense Therapeutics in a research report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price target on the stock. Finally, D. Boral Capital reissued a “buy” rating and issued a $14.00 price target on shares of NeuroSense Therapeutics in a research report on Wednesday, April 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $8.50.

NeuroSense Therapeutics Trading Down 6.6%

The stock’s fifty day moving average is $0.78 and its two-hundred day moving average is $0.86. The firm has a market cap of $22.37 million, a P/E ratio of -1.27 and a beta of 1.56.

Institutional Trading of NeuroSense Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP bought a new stake in NeuroSense Therapeutics during the 3rd quarter worth approximately $26,000. Jane Street Group LLC bought a new stake in NeuroSense Therapeutics during the 2nd quarter worth approximately $54,000. Squarepoint Ops LLC increased its holdings in NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after acquiring an additional 45,450 shares during the period. Finally, Yorkville Advisors Global LP bought a new stake in NeuroSense Therapeutics during the 4th quarter worth approximately $77,000. Institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.